MSD Receives European Approval of its Atypical Antipsychotic Medication SYCREST® (asenapine) for the Treatment of Manic Episodes in Bipolar I Disorder
MSD (MSD is a tradename of Merck & Co., Inc., with headquarters in
Whitehouse Station, N.J., U.S.A). announced today that the European
Commission has approved the Marketing Authorization Application (MAA)
for SYCREST® (asenapine) sublingual […]